Skip to content
Open access

The CMPK2–mtDNA axis mediates doxorubicin cardiotoxicity: mechanistic links to STAT1 transcription and FAD-mediated inhibition

Sep 2026 · Cellular & Molecular Biology Letters · 0 citations

TL;DR

CMPK2 is established as a key mediator of doxorubicin cardiotoxicity, integrating STAT1-mediated transcriptional regulation with mtDNA-dependent NLRP3 inflammasome activation into a unified pathological axis, addressing a major challenge in cardio-oncology.

Abstract

Doxorubicin is a widely used chemotherapeutic agent whose clinical utility is limited by dose-dependent cardiotoxicity. The precise mechanisms bridging mitochondrial dysfunction to cardiac inflammatory responses remain poorly defined. We utilized cardiomyocyte-specific CMPK2 knockout and overexpression mouse models, along with AAV9-mediated cardiac gene delivery in vivo and molecular assays in vitro, to define the role of the mitochondrial nucleotide metabolic enzyme CMPK2 in doxorubicin-induced cardiomyopathy. Tumor-bearing mouse models were employed to evaluate the impact on antitumor efficacy. CMPK2 expression was significantly upregulated in doxorubicin-injured hearts. Cardiomyocyte-specific CMPK2 overexpression exacerbated DOX-induced cardiac dysfunction, atrophy, oxidative stress, and fibrosis, whereas CMPK2 knockdown attenuated these pathological alterations. Mechanistically, CMPK2 drove oxidative mitochondrial DNA damage and cytosolic leakage, subsequently triggering NLRP3 inflammasome activation. We further identified STAT1 as a transcriptional activator of CMPK2. Importantly, the natural coenzyme flavin adenine dinucleotide directly bound to CMPK2 and blocked its downstream signaling. Flavin adenine dinucleotide administration mitigated doxorubicin-induced cardiac injury without compromising its antitumor efficacy in mice. Our study establishes CMPK2 as a key mediator of doxorubicin cardiotoxicity, integrating STAT1-mediated transcriptional regulation with mtDNA-dependent NLRP3 inflammasome activation into a unified pathological axis. Targeting this axis with flavin adenine dinucleotide represents a promising and selective cardioprotective strategy, addressing a major challenge in cardio-oncology.

Read PDF

Similar papers

Open access Oct 2026

ATF4 alleviates doxorubicin-induced cardiomyopathy by promoting H2S production and antioxidant defense.

Doxorubicin (DOX) remains a cornerstone in cancer treatment. However, its clinical utilization is significantly hampered by dose-dependent cardiotoxicity. The generation of reactive oxygen species (ROS) constitutes the central component of the pathogenesis of DOX-induced cardiotoxicity. Activating transcription factor...

Shu-Ting Xu, Yan Shi, Xiao-Shuai Zhao et al. · 0 citations
Oct 2026

Isoliquiritigenin attenuates doxorubicin-induced cardiomyopathy by alleviating mitochondrial dysfunction and oxidative damage through the Piezo1/Ca²⁺/Pdk4 signaling axis.

BACKGROUND Doxorubicin (DOX) is widely employed as an antineoplastic agent in clinical settings, yet its therapeutic utility is constrained by dose-dependent cardiotoxicity, partly resulting from oxidative injury to cardiomyocytes and impairment of mitochondrial function. Hence, there is an urgent imperative to develop...

Y. Wang, Dan Yang, Zhuo Liu et al. · 0 citations
Open access Nov 2026

ABAT Overexpression Protects Against Doxorubicin-Induced Cardiotoxicity by Preserving Mitochondrial Homeostasis.

Doxorubicin is a widely used chemotherapeutic agent whose clinical application is limited by dose-dependent cardiotoxicity, with mitochondrial dysfunction being a central pathological mechanism. Gamma-aminobutyric acid transaminase (ABAT) is a mitochondrial matrix enzyme implicated in mitochondrial DNA (mtDNA) maintena...

Peng Yang, Rong Yang, Jing-Jing Guo et al. · 0 citations
Open access Oct 2026

Doxorubicin-induced cardiotoxicity: SESN2-directed FBXO7 ubiquitination of CRY1 restores glycolytic homeostasis.

Doxorubicin (DOX), a cornerstone anthracycline antineoplastic agent, induces cumulative, dose-limiting cardiotoxicity that remains a major barrier to its clinical use. Accumulating evidence suggests that maladaptive metabolic remodeling-particularly loss of glycolytic competence-contributes centrally to DOX-induced car...

Li-Yun Song, Ming-Rui Liu, N. Quan et al. · 0 citations
Open access Oct 2026

NAD+ supplementation improves cardiomyocyte resilience to doxorubicin-induced cardiotoxicity

The number of cancer survivors has markedly increased in recent years, bringing greater attention to cancer therapy-related therapy related to cardiac dysfunction (CTRCD). Anthracyclines, such as doxorubicin (DOXO), are widely used chemotherapeutics but are well known to induce oxidative stress, mitochondrial dys...

E. Gorica, M. Ambrus, A. El Khal et al. · 0 citations
Sep 2026

DDR2 deficiency attenuates doxorubicin-induced cardiotoxicity by reducing cardiac dysfunction and oxidative stress in mice.

Doxorubicin (DOX) is a highly effective anthracycline chemotherapeutic drug. However, the clinical application is limited due to its dose-dependent cardiotoxicity. Discoidin domain receptor 2 (DDR2), the main collagen-binding receptor tyrosine kinase is a major player of various degrees of fibrosis or tissue restructur...

Yi-Han Zhang, Bo-Wei Xu, Jun-Qiang Feng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.